Scientists elucidated Raddeanin A’s significant antitumor efficacy against glioblastoma in vitro and in vivo by targeting pathways linked to stemness and epithelial-mesenchymal transition, chiefly via the downregulation of S phase kinase-associated protein 2 (Skp2).
[Journal of Cancer]
